StartsidaSGIOY • OTCMKTS
add
Shionogi 2 ADR Representing 1 Ord Shs
Föregående stängning
6,93 $
Dygnsintervall
6,94 $ - 7,03 $
Årsintervall
6,22 $ - 9,11 $
Börsvärde
1,87 bn JPY
Genomsnittlig volym
233,49 tn
Aktuellt
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
| (JPY) | sep. 2024info | Förändring Y/Y |
|---|---|---|
Intäkter | 116,38 md | −4,00 % |
Rörliga kostnader | 52,93 md | −3,66 % |
Nettoinkomst | 52,50 md | 9,30 % |
Nettovinstmarginal | 45,11 | 13,86 % |
Vinst per aktie | — | — |
EBITDA | 53,13 md | −5,14 % |
Giltig skattesats | 8,28 % | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
| (JPY) | sep. 2024info | Förändring Y/Y |
|---|---|---|
Kontanta och kortsiktiga investeringar | 303,40 md | 20,22 % |
Totala tillgångar | 1,46 bn | 3,34 % |
Totala ansvarsskyldigheter | 145,93 md | −18,09 % |
Totala tillgångar | 1,31 bn | — |
Utestående aktier | 850,69 mn | — |
P/B | 0,00 | — |
Avkastning på tillgångar | 8,22 % | — |
Avkastning på kapital | 9,10 % | — |
Kassaflöde
Förändring i nettokassa
| (JPY) | sep. 2024info | Förändring Y/Y |
|---|---|---|
Nettoinkomst | 52,50 md | 9,30 % |
Kontanter från verksamhet | 45,30 md | 220,14 % |
Kontanter från investering | −17,63 md | 47,30 % |
Kontanter från finansiering | −1,11 md | 94,50 % |
Förändring i nettokassa | 21,45 md | 158,43 % |
Fritt kassaflöde | 8,02 md | 135,46 % |
Om
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Grundades
1878
Huvudkontor
Hemsida
Anställda
4 959
